Cannabis for PTSD in Australia — Evidence, Products & How to Access Treatment (2026)

Post-traumatic stress disorder affects an estimated 1.16 million Australians at any given time, making it one of the most prevalent mental health conditions in the country. Veterans, first responders, sexual assault survivors and people who have experienced serious accidents or natural disasters are disproportionately represented — but PTSD can affect anyone who has experienced severe trauma. Conventional treatments including SSRIs, trauma-focused psychotherapy and eye movement desensitisation and reprocessing (EMDR) are effective for many patients, but a significant proportion — up to 40% — do not achieve full remission.

It is against this backdrop that medicinal cannabis has become one of the most discussed and most prescribed treatments in Australian PTSD management. Australia’s Department of Veterans’ Affairs (DVA) now funds medicinal cannabis for eligible veterans with PTSD, a recognition that reflects both the scale of need and the strength of emerging evidence.

This is a complete, evidence-based guide to cannabis for PTSD in Australia — including what the research actually shows, which products are most relevant, how to dose, and how to access a prescription.

How PTSD affects the brain — and where cannabis fits in

PTSD is a disorder of fear memory and threat regulation. Following trauma, the brain’s fear circuits — centred on the amygdala, prefrontal cortex and hippocampus — become dysregulated in ways that cause intrusive memories, hyperarousal, avoidance and emotional numbing to persist long after the danger has passed.

Three neurobiological features of PTSD are particularly relevant to cannabis:

1. Endocannabinoid deficiency. Research published in Molecular Psychiatry found that PTSD patients have significantly lower levels of anandamide (the brain’s primary endocannabinoid) and a higher density of CB1 receptors in the amygdala — consistent with a system that is chronically underactive. This endocannabinoid deficiency appears to impair the brain’s ability to extinguish fear memories, which is a core mechanism of PTSD maintenance.

2. Hyperactive amygdala. The amygdala, which processes threat detection and fear responses, is tonically overactivated in PTSD. CB1 receptors are densely expressed in the amygdala; cannabinoids that activate these receptors (primarily THC and to a lesser extent CBD) reduce amygdala reactivity to threatening stimuli.

3. Disrupted REM sleep. PTSD hijacks REM sleep — the stage where emotional memories are processed — producing traumatic nightmares that both consolidate the trauma and prevent restorative sleep. THC suppresses REM sleep, which directly reduces nightmare frequency and intensity. This is one of the most clinically documented effects of cannabis in PTSD treatment.

What the clinical research shows

The evidence base for cannabis in PTSD is stronger than for most other psychiatric indications, though it remains far from definitive.

Nightmare reduction: A 2009 open-label study of nabilone (a synthetic THC analogue) in 47 Canadian military veterans with treatment-resistant PTSD nightmares found that 72% of patients reported cessation or significant reduction of nightmares. Mean nightmare score decreased from 6.8 to 1.7 on a validated scale. This remains one of the most replicated findings in cannabis-PTSD research. Multiple subsequent case series support the same effect.

Overall PTSD symptom reduction: A 2014 retrospective chart review published in the Journal of Psychoactive Drugs found that PTSD patients using cannabis reported an average 75% decrease in PTSD Checklist (PCL) scores compared to periods without cannabis use. While retrospective data has significant limitations, the magnitude of self-reported benefit was notable.

Sleep quality: Multiple studies document improved sleep onset, reduced nocturnal awakening and improved subjective sleep quality in PTSD patients using THC-containing cannabis. The nightmare-suppressing effect of THC appears to be the primary mechanism, though anxiolytic and muscle-relaxant effects also contribute.

Anxiety and hyperarousal: CBD in particular has demonstrated anxiolytic effects in PTSD-adjacent presentations. A 2019 case series published in The Permanente Journal noted significant reductions in PTSD-related anxiety after CBD treatment in a series of patients, with improvements maintained at follow-up.

Important limitations: Most positive studies are observational or retrospective. A 2022 randomised controlled trial (PTSD cannabis trial) found mixed results, with significant placebo response in the control arm. The evidence supports cannabis as an adjunct to — not a replacement for — trauma-focused psychotherapy.

THC vs CBD for PTSD: which one works better?

	THC-dominant	CBD-dominant	Balanced (THC:CBD 1:1 to 4:1)
Nightmare suppression	Strong — primary mechanism	Minimal direct effect	Moderate
Anxiety reduction	Dose-dependent — helps at low doses, worsens at high	Consistent anxiolytic	Good across dose ranges
Sleep quality	Improves onset and maintenance	Improves via anxiety reduction	Comprehensive effect
Hyperarousal	Reduces via CB1 agonism	Reduces via 5-HT1A	Dual mechanism
Long-term use risk	Tolerance, REM suppression, dependence	Very low	Moderate
Day-use suitability	Limited — psychoactive	Excellent	Limited

The clinical verdict: Most Australian specialists prescribe a THC-dominant or balanced oil for evening/night use (to address nightmares and sleep) combined with CBD-dominant oil for daytime use (to address anxiety, hyperarousal and emotional reactivity). This split-dosing approach addresses PTSD’s full symptom profile while managing the risks of daytime THC impairment.

Best cannabis products for PTSD in Australia

Evening THC oil (first-line for nightmares)

A sublingual or swallowed THC-containing oil taken 1–2 hours before bed is the most commonly prescribed format for PTSD nightmares in Australia. Starting doses are typically 2.5–5mg THC, increasing gradually. The goal is nightmare suppression without significant morning grogginess.

Key consideration: Choose a full-spectrum or broad-spectrum product that includes CBD alongside THC. CBD buffers the psychoactive effects of THC and reduces the risk of THC-induced anxiety — a real concern in people with PTSD who may already have heightened physiological arousal.

Daytime CBD oil (for anxiety and hyperarousal)

High-CBD, low-THC oils taken morning and midday address daytime anxiety, emotional dysregulation and hypervigilance without the psychoactive effects of THC. Typical starting doses: 50–100mg CBD twice daily, titrating upward over 4–8 weeks.

Vaporised low-THC flower (for acute dissociation or flashbacks)

Some patients with PTSD find that a small amount of vaporised low-THC, high-CBD flower provides rapid relief during acute flashback episodes or dissociative states. Onset is 5–15 minutes. Strict dose control is essential — one or two inhalations of a low-THC strain (under 12% THC) only. High-THC flower can trigger or intensify dissociation in PTSD-vulnerable individuals.

What to avoid

• High-THC concentrates or edibles without CBD: The rapid, intense THC exposure can trigger paranoia, dissociation or panic — particularly problematic in PTSD where the trauma response is already primed
• Sativa-dominant, high-pinene strains: Stimulating terpene profiles can increase hyperarousal
• Cannabis used as avoidance: Cannabis can become a way to numb emotions rather than process trauma. Used this way, it impairs the emotional processing that psychotherapy requires

Important: Cannabis is not a replacement for trauma-focused psychotherapy (Prolonged Exposure, Cognitive Processing Therapy or EMDR). The strongest outcomes occur when cannabis manages symptoms enough to allow patients to engage fully in psychotherapy. Discuss this integration with your prescribing doctor.

Dosing cannabis for PTSD: practical guidance

Nighttime (THC-dominant, for nightmares and sleep):

• Start: 2.5mg THC (with CBD if possible), 60–90 minutes before sleep
• Increase by 2.5mg every 5–7 nights if nightmares persist
• Most patients find their nightmare-suppressing dose between 5–15mg THC
• Avoid exceeding 20mg THC — higher doses increase the risk of next-day impairment and dependence

Daytime (CBD-dominant, for anxiety and hyperarousal):

• Start: 50mg CBD morning and midday
• Increase to 75–100mg per dose if insufficient response after 2 weeks
• Keep a daily symptom diary to track anxiety, hyperarousal and mood

If using THC during the day:

• Limit to 1–2.5mg THC — this is the range where anxiety reduction is most consistent in THC-naive and PTSD patients
• Do not drive after any daytime THC dose
• Titrate very conservatively — PTSD patients can be more sensitive to THC’s anxiogenic effects

DVA funding for veterans with PTSD

Australia’s Department of Veterans’ Affairs now funds medicinal cannabis for eligible veterans with PTSD under the DVA’s Health Care Card and Gold Card arrangements. This is a significant development: it means eligible veterans may access treatment at significantly reduced or no out-of-pocket cost.

Eligibility requirements and approved products change periodically. Contact DVA directly (1800 555 254) or ask your treating GP to check current arrangements. A referral from your GP or psychiatrist is typically required.

First responders (police, paramedics, firefighters) with PTSD are not covered by DVA arrangements but may be eligible for workers’ compensation-funded medicinal cannabis through their employer’s scheme, depending on the state and circumstances.

How to access a PTSD cannabis prescription in Australia

Step 1: Choose a prescribing pathway

• DVA-funded (veterans only): Ask your GP to refer through DVA. Current DVA arrangements may cover costs.
• Telehealth medicinal cannabis platforms: Alternaleaf, Polln and Leafio specialise in this. Initial consultations: $50–150. Appointments can typically be booked within days.
• Psychiatrist: If you are under active psychiatric care for PTSD, your psychiatrist may be able to prescribe or co-prescribe. Not all psychiatrists are comfortable with medicinal cannabis, but many now are, particularly those with veteran or trauma populations.

Step 2: Prepare for your consultation

Bring documentation of your PTSD diagnosis, your current medications, treatments you have previously tried (including which psychotherapies), and a brief symptom diary including nightmares per week, sleep quality, and daytime anxiety ratings.

Step 3: The prescription

Most PTSD cannabis prescriptions are issued under the TGA’s Special Access Scheme B (SAS-B), which requires no separate government approval. Your GP or telehealth prescriber handles the process. Medication is dispensed from a registered Australian pharmacy, typically delivered to your door within 2–7 business days.

Ongoing cost without DVA funding: $100–300/month depending on formulation and dose. Initial consultation: $50–150.

Cannabis and PTSD psychotherapy: the integration question

There is an important nuance that prescribers and patients need to discuss openly: cannabis can both help and hinder PTSD therapy depending on how it is used.

Used well: Cannabis reduces the severity of intrusive symptoms (nightmares, hyperarousal, avoidance-driving anxiety) to a level where patients can engage with therapy more fully. Many patients describe finally being able to stay in a Prolonged Exposure session without leaving when their cannabis-managed anxiety was lower. CBD in particular may facilitate trauma processing by reducing the amygdala’s threat-detection overactivity.

Used poorly: Cannabis used as an emotional avoidance tool — taking THC whenever distressing memories arise rather than sitting with the emotion as therapy requires — impairs the very processing that therapy is trying to build. This is a recognised risk, particularly in patients with pre-existing cannabis use disorder.

The safest integration: use cannabis to manage sleep and baseline hyperarousal, not as a real-time response to emotional distress. Discuss your cannabis use openly with your therapist.

Frequently asked questions

Is medicinal cannabis approved for PTSD in Australia? Medicinal cannabis is not formally “approved” for PTSD by the TGA in the same way a listed medicine is. However, it is widely prescribed for PTSD under the TGA’s Special Access Scheme B (SAS-B), which allows GPs and specialists to prescribe unapproved therapeutic goods for specific patients. PTSD is one of the most common indications for which medicinal cannabis is prescribed in Australia.

Does cannabis help PTSD nightmares? Yes — THC suppresses REM sleep, which is the sleep stage in which nightmares occur. Multiple studies and clinical reports document significant reductions in nightmare frequency and intensity with low-to-moderate dose THC-containing cannabis. This is currently one of the strongest clinical evidence points for medicinal cannabis in PTSD management.

Can I get medicinal cannabis for PTSD on the PBS in Australia? No. Medicinal cannabis is not currently listed on the Pharmaceutical Benefits Scheme (PBS) in Australia. Veterans may access DVA-funded medicinal cannabis for PTSD. All other patients pay out of pocket. Costs typically range from $100–300 per month.

Can you use cannabis for PTSD while taking antidepressants or prazosin? CBD can interact with antidepressants via the CYP450 enzyme pathway. THC and sedatives (including prazosin) have additive sedative effects — this may be clinically useful at low doses but warrants monitoring. Always disclose cannabis use to your prescribing doctor before starting. Read our full drug interaction guide.

Will cannabis make PTSD worse? High-THC products can worsen paranoia, dissociation and hypervigilance in PTSD-sensitive individuals, particularly at higher doses or without CBD present. The risk is dose-dependent. CBD-only or high-CBD, low-THC products are generally well-tolerated. Start with the lowest effective dose and titrate under medical supervision.

How long does it take for cannabis to help PTSD? Sleep improvements (particularly nightmare reduction) can appear within the first 1–2 weeks with THC-containing products. Daytime anxiety and hyperarousal improvements with CBD typically take 4–8 weeks of consistent use to reach full effect. Overall PTSD symptom reduction should be assessed at 8–12 weeks.

Can first responders with PTSD access medicinal cannabis? Yes. First responders are not covered by DVA arrangements but can access medicinal cannabis through the same telehealth prescription pathway as any Australian patient. Some workers’ compensation schemes in certain states fund medicinal cannabis treatment — check with your HR department or union representative.

Is cannabis safe to combine with trauma therapy (PE, CPT or EMDR)? Used correctly, cannabis can complement trauma therapy by reducing the severity of between-session symptoms. The key is not using cannabis as emotional avoidance. Discuss your cannabis use openly with your therapist — most trauma-focused therapists in Australia are now familiar with medicinal cannabis and can help you integrate it thoughtfully.